Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
FRα BsAb - 01 | PCC | Solid Tumor | Ovarian cancer,Non-small cell lung cancer |
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
FRα BsAb-ADC | Bispecific antibody | Oncology/Cancer | Ovarian cancer | Preclinical | Global |
Expression analysis of human FOLR1 on HEK293/Human FOLR1 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human FOLR1 Stable Cell Line or negative control cell using PE-labeled anti-human FOLR1 antibody.
5e5 of anti-FOLR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FOLR1, His Tag (Cat. No. FO1-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Biotinylated Human FOLR1, His,Avitag (Cat. No. FO1-H82E2) immobilized on SA Chip can bind Folic acid-BSA with an affinity constant of 83.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Folinic Acid | FTHF | Approved | Anemia; Autism Spectrum Disorder; Down Syndrome; Rectal Neoplasms; Diarrhea; Vitamin B 12 Deficiency; Colorectal Neoplasms | Details | ||||||
Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Neoplasms; Breast Neoplasms; Pituitary Neoplasms; Lung Neoplasms | Details |
Mirvetuximab soravtansine | M9346-Asulfo-SPDB-DM4; IMGN-853 | Approved | Immunogen Inc | United States | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Immunogen Inc | 2022-11-14 | Ovarian Neoplasms; Solid tumours; Cystadenoma, Serous; Carcinoma, Ovarian Epithelial; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Carcinosarcoma; Adenocarcinoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
MOv19-BBz CAR-T cells Therapy | University Of Pennsylvania | Details | |||
Epofolate | BMS-753493 | Bristol-Myers Squibb Company, Novartis Pharma Ag | Details | ||
BAT-8006 | BAT8006; BAT-8006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
ELU-001 | ELU-001 | Phase 2 Clinical | Elucida Oncology Inc | Cholangiocarcinoma; Neoplasm Metastasis; Carcinoma, Endometrioid; Adenocarcinoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Biliary Tract Neoplasms; Klatskin Tumor; Colonic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Stomach Neoplasms; Rectal Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Uterine Diseases | Details |
PRO-1184 | PRO-1184 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Eisai Co Ltd, Morphotek Inc, Bristol-Myers Squibb Company | Ovarian Neoplasms; Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Luveltamab tazevibulin | SP-7219; DBCO-Alexa647-conjugated SP7219; STRO-002; SP-7675; SP-7676 | Phase 1 Clinical | Sutro Biopharma Inc | Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid | Details |
MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | King'S College London, Cancer Research UK | Ovarian Neoplasms; Neoplasms | Details |
Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
CBP-1008 | CBP-1008 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell | Details |
This web search service is supported by Google Inc.